were 29 men and 21 women. Reasons for admission in the control patients are shown in Table 1 .
Summary
To assess the aetiological contribution made to spontaneous epistaxis in adults over the age of 50 years by various groups of drugs, a controlled study was designed. Fifty-three consecutive epistaxis patients were compared with 50 controls. Significant differences were found between the groups in their consumption of warfarin, dipyridamole and non-steroidal antiinflammatory drugs. Hypertension was equally common in the two groups, but tended to be less well controlled in the epistaxis patients compared to the controls.
It is thought that the link between the use of nonsteroidal anti-inflammatory drugs and the occurrence of epistaxis may be due to alteration of platelet function. 
Introduction
Epistaxis is a very common ENT emergency, particularly amongst older patients. Indeed, out of a total of 364 emergency admissions into our unit for the whole year of 1987, no less than 153 (42%) were due to epistaxis. Known aetiological factors include trauma, local inflammation, hypertension, clotting diatheses, blood vessel abnormalities (such as Osler-Rendu-Weber disease), and nasal tumours. Many drugs have been reported to cause epistaxis, including warfarin', dipyridamole-, thloridazine", various eye drops", and even the oral contraceptive pill". It was our firm impression that a significant number of elderly epistaxis patients were taking non-steroidal anti-inflammatory drugs (NSAIDs). This study was designed to investigate the aetiological contribution made by various groups of drugs in a prospective, controlled manner.
Method
The study group consisted of 53 consecutive patients over the age of 50 years admitted to a single ENT unit with epistaxis over four months. The control group consisted of 50 consecutive patients matched for age admitted to the same ward as the study group over the same time period, with diagnoses other than epistaxis. In both groups, a detailed enquiry was made into the patients' current drug consumption. Past medical history and blood pressure at the time of admission were also noted. Details of the treatment required to control the epistaxis were recorded for the study group.
Results
In the study group of 53 patients, the median age was 68 years (range 56-87 years). There were 29 men and 24 women. In the control group of 50 patients, the median age was 64 years (range 51-89 years). There
Past medical history
There were 15 patients in each group who gave a history of hypertension. On admission, average blood pressure for the epistaxis patients was 161/93 mmHg, as opposed to 140/83 for the control group. This difference was statistically significant both for systolic (Student's r-test, P<0.002) and diastolic (P=O.OI) values. Chronic obstructive airways disease was more common in the study group than the controls (21% compared to 14%), as was ischaemic heart disease (11% compared to 4%).A history of arthritis was much more common in the epistaxis patients (23% compared to 8%). Eleven (21%) of the study group had suffered a previous epistaxis requiring medical treatment, whereas none of the control patients gave such a history. Conversely, the control group were more prone to both diabetes (8% compared to 2%) and peptic ulcer/gastritis (12% compared to 4%). No epistaxis patients had clotting diatheses (though one had Osler-Rendu-Weber disease), and none of them admitted to recent trauma.
Drug history
Differences were found between the groups in their consumption of NSAIDs, dipyridamole and warfarin, as shown in Table 2 . These drugs were used by 22 (42%) of the epistaxis patients compared to 3 (6%) of the controls, and these differences are statistically significant [x 2 = 18.105 (3 df) P<0.0005]. When the difference between the groups for NSAIDs is analysed separately, it remains significant [x 2 = 8.463 (1 df with Yates' correction), P< 0.005]. The actual members of the NSAID group involved are shown in Table 3 .
Striking differences were noted in the antihypertensive medication used by the two groups, as shown in Table 4 . Only one hypertensive (7%) of 15 in the epistaxis group was on fj·blockers, compared 
Discussion
Epistaxis complicating drug therapy in patients receiving warfarin and dipyridamole has been well documented. However, our interest in drug-induced epistaxis is centred on the hitherto unrecognized problem of non-steroidal anti-inflammatory drugs. A wide variety of commercially available NSAIDs are commonly prescribed to the over-fifties who present to their general practitioner with traumatic or degenerative joint disorders, and some may now be bought over the counter. New trends in the management of cardiovascular diseases with low-dose aspirin are the subject of several recent reports? The common mode of action of these drugs lies in their alteration of arachidonic acid metabolism, chiefly involving the cyclo-oxygenase pathway: they therefore may have an effect on platelet function. Such an effect has been demonstrated". Aspirin interferes with the function of a platelet on a permanent basis, but the other NSAIDs probably have a reversible effect. Gastrointestinal bleeding as a complication of NSAID therapy has received widespread recognition, with one recent report suggesting that up to one-third of the elderly patients with bleeding peptic ulcers have taken these drugs", In otolaryngology, however, the only area of interest until now has been the association of postoperative bleeding following tonsillectomy and aspirin ingeetion'P-". Our present prospective study clearly indicates a statistically significant correlation between NSAID therapy and nasal haemorrhage when the epistaxis and control groups are compared (P< 0.005). Indeed, it would seem that in 19/53 cases (36%), a pharmacological component could be implicated in the causation of epistaxis. From the admission figures given earlier, this would mean 55 cases per year in our unit.
A significant proportion of patients with epistaxis had 'arthritis' (23%) when compared to the control group (8%). It is not possible from the data in the current study to decide with certainty whether some abnormality associated with an 'arthritic' condition is responsible for an increased incidence of epistaxis in the study group. We have therefore begun a further study to examine platelet function in some detail in patients taking NSAIDs who develop epistaxis.
It is our conviction that doctors and their patients should in future be warned of the possible risk of epistaxis as well as gastrointestinal haemorrhage before commencing NSAID treatment. Perhaps a history of previous epistaxis should be taken as a relative contra-indication to the use of NSAIDs. The risk has been reported to the Committee on Safety of Medicines, and should perhaps be mentioned on the relevant drug data sheets by their manufacturers. (2 df), P < 0.01]. Only three of the hypertensive patients with nose bleeds were taking NSAIDs, and so no evidence of an interaction between hypertension and NSAID consumption as aetiological factors in epistaxis was found. No differences were found between the groups for any other types of drugs, and we did not find any evidence to suggest that drug interactions could be blamed for causing epistaxis in our patients.
Treatment
Nasal cautery was performed in 16 patients. Silver nitrate sticks were used on 13 occasions, with subsequent packing being required in four ofthese. Hotwire electrocautery was used in three cases: none of these needed packs. Nasal packs were inserted as primary treatment in 37 cases: these were balloon packs (34) or bismuth and iodoform paste packs (3) . Repacking was only required in three of these patients. Despite our unit having a policy of early surgical intervention in difficult cases", arterial ligation was not necessary on any of our patients. Whilst intravenous drips were inserted as a precaution in all cases, blood transfusion was only given to two patients. No significant differences were found between the treatment required by patients taking NSAIDs and those who were not. 
